Seladelpar: New hope for patients with primary biliary cholangitis.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-05-10 DOI:10.1016/j.medj.2024.03.019

Yulia A Nevzorova, Francisco Javier Cubero

引用次数: 0

Abstract

The study by Hirschfield et al.¹ demonstrated safety profile and clinically significant effectiveness of the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar in patients with primary biliary cholangitis, highlighting its plausible use as a second-line treatment to reduce disease activity and pruritus.

查看原文本刊更多论文

Seladelpar：原发性胆汁性胆管炎患者的新希望。

赫希菲尔德等人1 的研究表明，过氧化物酶体增殖激活受体δ（PPARδ）激动剂塞拉得尔帕对原发性胆汁性胆管炎患者具有安全性和显著的临床疗效，这突出表明它可以作为二线治疗药物用于减少疾病活动和瘙痒。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.